Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Clinical trial NCT03715205 · COMPLETED
Trial details
- NCT number
- NCT03715205
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2024-08-21
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.